NSAIDs Do Not Worsen Depression
Based on the highest quality evidence, NSAIDs do not worsen depression and may actually improve depressive symptoms, particularly selective COX-2 inhibitors like celecoxib. The most robust data from a 2014 meta-analysis of 14 randomized controlled trials involving 6,262 participants demonstrates that anti-inflammatory treatment, including NSAIDs, significantly reduces depressive symptoms 1.
Evidence Hierarchy and Quality
The available guidelines 2, 3 focus exclusively on cardiovascular and gastrointestinal risks of NSAIDs—they make no mention of psychiatric or mood effects. This absence in major clinical guidelines suggests psychiatric worsening is not a recognized class effect requiring clinical warnings.
Strongest Evidence: NSAIDs May Improve Depression
The 2014 JAMA Psychiatry meta-analysis 1 found:
- Overall reduction in depressive symptoms (SMD -0.34) with anti-inflammatory treatment
- Celecoxib specifically showed benefit for remission (OR 7.89) and response (OR 6.59)
- No increased adverse effects at 6-12 weeks compared to placebo
A 2024 systematic review in children/adolescents 4 corroborated these findings with a small but significant effect (SMD -0.29) favoring anti-inflammatory agents.
Contradictory Evidence: Case Reports vs. Population Studies
The concern about NSAIDs worsening depression stems from low-quality case reports 5, 6 describing 4-5 psychiatric patients who developed depression while taking NSAIDs. However, these 1990s case series have critical limitations:
- No control groups
- Patients already had psychiatric disorders
- Temporal associations don't prove causation
- Never replicated in controlled trials
Two pharmacovigilance studies 7, 8 attempted to validate these concerns but found conflicting results:
The 2012 study 7 initially suggested NSAID exposure increased treatment-resistant depression (OR 1.55), but this association disappeared after adjusting for confounding variables—meaning the effect was likely due to patient characteristics (age, comorbidities) rather than NSAIDs themselves.
The GENDEP study 8 with 811 MDD patients found no effect of NSAIDs on antidepressant efficacy with either escitalopram or nortriptyline after controlling for confounders.
Clinical Algorithm
For patients with depression requiring pain management:
- NSAIDs are safe to use and do not worsen depression based on controlled trial data
- Consider celecoxib preferentially if anti-inflammatory effect might benefit mood (SMD -0.29) 1
- Monitor for drug-drug interactions rather than mood worsening:
- Standard NSAID precautions apply (cardiovascular, GI, renal risks per FDA warnings) 2, 3
Critical Caveats
The 2025 FAERS data mining study 9 identifies the real concern: NSAIDs combined with SSRIs may increase risks of bleeding, thrombocytopenia, and acute kidney injury—but not psychiatric worsening. This represents a pharmacological interaction risk, not a mood effect.
If a patient appears to worsen psychiatrically on NSAIDs, consider:
- Confounding by indication (pain/inflammation causing mood symptoms)
- Underlying disease progression
- Other medication changes
- The case reports 5, 6 suggest rare idiosyncratic reactions are theoretically possible, but this has never been demonstrated in controlled settings
The evidence strongly favors NSAIDs being neutral-to-beneficial for mood, with the primary concerns being standard NSAID adverse effects (cardiovascular, GI, renal) and drug-drug interactions with antidepressants—not psychiatric deterioration.